Amyloid-β positron emission tomography in the diagnostic evaluation of alzheimer disease summary of primary findings and conclusions

JAMA Internal Medicine

Volumn 174, Issue 1, 2014, Pages 133-134

  Pearson, Steven D ^a   Ollendorf, Daniel A ^a   Colby, Jennifer A ^a  

^a INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AMYLOID BETA POSITRON EMISSION TOMOGRAPHY; CLINICAL PRACTICE; COMMUNITY CARE; DIAGNOSTIC TEST ACCURACY STUDY; FOOD AND DRUG ADMINISTRATION; HUMAN; LONG TERM CARE; MEDICAID; MEDICAL LITERATURE; MEDICARE; MENTAL DETERIORATION; MILD COGNITIVE IMPAIRMENT; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; ETHYLENE GLYCOLS; EVIDENCE-BASED MEDICINE; FLUORINE RADIOISOTOPES; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS;

EID: 84892420697     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.11711     Document Type: Review

References (8)

1. Yang L, Rieves D, Ganley C. Brain amyloid imaging - FDA approval of florbetapir F18 injection. N Engl J Med. 2012;367(10):885-887.
2. Institute for Clinical and Economic Review. Diagnostic tests for Alzheimer's disease: generating and evaluating evidence to inform insurance coverage policy 2012. www.icer-review.org/index.php/Completed-Appraisals/ alzheimers.html. Accessed August 30, 2013.
3. Centers for Medicare and Medicaid Services. Proposed decision memo for beta amyloid positron emission tomography in dementia and neurodegenerative disease (CAG-00431N). www.cms.gov/medicare-coverage-database/details/nca- proposed-decision-memo.aspx?NCAId=265. Accessed September 3, 2013.
4. Fryback DG, Thornbury JR The efficacy of diagnostic imaging. Med Decis Making. 1991;11(2):88-94.
5. Clark CM, Pontecorvo MJ, Beach T.G., et al.; AV-45-A16 Study Group. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669-678.
6. Doraiswamy PM, Sperling RA, Coleman R.E., et al.; AV45-A11 Study Group. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79(16):1636-1644.
7. Grundman M, Pontecorvo MJ, Salloway S.P., et al.; 45-A17 Study Group. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013;27(1):4-15.
8. Jack CR J.r., Lowe VJ, Weigand S.D., et al.; Alzheimer's Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132(pt 5):1355-1365.